• ¿Documento equivocado? Cámbialo gratis
  • Escrito por estudiantes que aprobaron
  • Inmediatamente disponible después del pago
  • Leer en línea o como PDF
Vender
¿Dónde estudias?
Tu idioma
Document preview thumbnail
Vista previa 2 fuera de 15 páginas
Examen

RAC

Document preview thumbnail
Vista previa 2 fuera de 15 páginas

Administrative Procedure Act federal law enacted in 1946, "notice and comment rulemaking" 1906: The Pure Food and Drug Act (PFDA) interstate commerce labeling 1912 Pure Food and Drug Act revised in 1912, stated that a drug was misbranded if its label contained a "false and fraudulent" statement regarding "curative or therapeutic effect." 1938 FD&C Act • extended control to cosmetics and therapeutic devices • required new drugs to be shown safe before marketing, beginning a new system of drug regulation • eliminated the Sherley Amendment requirement to prove intent to defraud in drug misbranding cases Durham-Humphrey Amendment of 1951 • Created a distinction between "OTC" and "Legend Drugs". • Legend Drugs can only be dispensed with a valid Prescription.. • Required Legend Drugs to carry the statement: "Caution: Federal law prohibits dispensing without a prescription.". • Most people refer to Legend drugs simply as "Prescription Drugs". • The emphasis on this act was to insure safety thru qualified medical supervision. Kefauver-Harris Amendments of 1962 efficacy as well as safety informed consent for research subjects FDA regulates advertising of rx drugs established GMP Drug advertising from FTC to FDA Medical Device Amendments of 1976 -classification of devices according to their function -premarket approval -establishment of performance standards -conformance with GMP regulations -adherence to record and reporting requirements Safe Medical Devices Act of 1990 Postmarketing Authority User Facilities Recall Authority MDUFMA, Medical Device User Fee and Modernization Act of 2002 Medical Device User Fee and Modernization Act of 2002: Similar to the Prescription Drug User Fee Act (PDUFA) in many ways. Requires that was driven by the need to speed up the Premarket Approval (PMA) device and 510(k) clearances. Under MDUFMA, fees were established for PMAs, product development protocols, biologics license applications (BLA), certain supplements and 510(k)s in order to speed up the review processes. The Medical Device User Fee Amendments of 2012 Expanded user fees and performance goals Orphan Drug Act of 1983 Provides incentives to promote research, approval, and marketing of drugs needed for the treatment of rare diseases. Hatch-Waxman Act of 1984 Encouraged the creation of both generic and new medications by streamlining the process for generic drug approval and by extending patent licenses. Prescription drug user fee act of 1992 This act states that manufacturers must pay a user fee along with each drug that is marketed, facility that manufacturers drugs, and each app from approval.The money is used to hire drug reviewers and facilitate the drug approval process. Food and Drug Administration Modernization Act of 1997 additional authority for monitoring the progress of drug and biologic postmarketing studies The law codified the expedited review policy for certain medical devices, amended and clarified the humanitarian device provisions of SMDA FDA to recognize international or other national standards Agreement Meetings and Determination Meetings Pediatric Research Equity Act of 2003 act that authorizes the FDA to require research of pediatric uses for new drugs FDAAA 2007 Required registration FDAAA reauthorized a number of key programs, including PDUFA, MDUFMA and PREA 21 CFR 0-99 Protection of Human Subjects 21 CFR 100s Food 21 CFR 200s Labeling, CGMPs, Controlled Substances 21 CFR 300s Human Drugs 21 CFR 500s Animal Drugs 21 CFR 600s Biologics 21 CFR 800s Devices 21 CFR 1270 Human Tissues for Transplant 21 CFR 1271 Human Cell and Tissue Products 21 CFR 820 Quality System (QS) Regulation/Medical Device Good Manufacturing Practices Pathway: Right to Reference Original NDA = NDA Supplment Pathway: No right of Reference to Original NDA= 505(b)(2) Pathway: Similar to RLD, Same Labeling Suitability Petition Pathway: Same as RLD ANDA (CMC, Fasted and Fed BE, Crossover) AKA: ANDA 505(j) AKA: NDA Submission with no right of reference 505(b)(2) AKA: New NDA 505(b)(1) ANDA Paragraph 1 Patent information has not been filed ANDA Paragraph 2 Patent has expired ANDA Paragraph 3 Patent will expire on x date ANDA Para


Información del documento

Subido en
6 de junio de 2024
Número de páginas
15
Escrito en
2023/2024
Tipo
Examen
Contiene
Preguntas y respuestas
$11.99

¿Documento equivocado? Cámbialo gratis Dentro de los 14 días posteriores a la compra y antes de descargarlo, puedes elegir otro documento. Puedes gastar el importe de nuevo.
Escrito por estudiantes que aprobaron
Inmediatamente disponible después del pago
Leer en línea o como PDF

Vendido
1
Seguidores
0
Artículos
1124
Última venta
-



Por qué los estudiantes eligen Stuvia

Creado por compañeros estudiantes, verificado por reseñas

Calidad en la que puedes confiar: escrito por estudiantes que aprobaron y evaluado por otros que han usado estos resúmenes.

¿No estás satisfecho? Elige otro documento

¡No te preocupes! Puedes elegir directamente otro documento que se ajuste mejor a lo que buscas.

Paga como quieras, empieza a estudiar al instante

Sin suscripción, sin compromisos. Paga como estés acostumbrado con tarjeta de crédito y descarga tu documento PDF inmediatamente.

Student with book image

“Comprado, descargado y aprobado. Así de fácil puede ser.”

Alisha Student

Preguntas frecuentes

Ups! No podemos cargar tu documento ahora. Inténtalo de nuevo o contacta con soporte.